Silicone Scar Gel Classification and Claim Substantiation: A US (FDA), EU and China (NMPA) Decision Matrix for Distributors and OEM Buyers

How is a silicone scar gel classified in the US, EU and China?

For international medical device distributors, brand owners, and private-label procurement teams, qualifying a silicone scar gel or sheeting product requires overcoming a common misconception: that a product's regulatory pathway is determined solely by its material chemistry. Silicone polymer fluids (such as cross-linked dimethicone, cyclopentasiloxane, and phenyl trimethicone) are chemically inert, bio-compatible materials widely used in both medical devices and top-tier topical cosmetics. However, when presented to regulatory authorities in Washington, Brussels, or Beijing, the exact same silicone polymer matrix is evaluated through fundamentally different regulatory lenses ¹⁵⁶.

Much like how a wound dressing's claim sets its regulatory class, a silicone scar gel's regulatory status across jurisdictions follows its stated intended purpose, mechanism of action, and target tissue state. If the label states that the gel 'creates a protective moisture-retentive occlusion layer to manage hypertrophic scars and keloids', it is governed as a medical device. If the label claims to 'soften and smooth dry, rough post-acne skin texture', it shifts into cosmetic territory in Europe. If the marketing team claims the product 'actively dissolves scar tissue and cures keloid tumors', it triggers drug enforcement in the United States and China.

The following multi-market regulatory decision matrix summarizes how the United States Food and Drug Administration (US FDA), European Union Medical Device Regulation (EU MDR), and China National Medical Products Administration (NMPA) classify silicone scar management products as of August 2026.

Understanding these baseline regulatory definitions is essential before drafting commercial packaging, negotiating private-label OEM manufacturing agreements, or submitting registration dossiers to national health authorities.

What are the US FDA 21 CFR 878.4025 rules and 510(k) predicate requirements?

In the United States, medical devices intended for scar management are regulated under 21 CFR 878.4025 ('Silicone sheeting for scar management'). The FDA defines a silicone scar management device as an intended item composed of silicone material that covers a scar tissue area to manage hyperproliferative (hypertrophic and keloid) scars ¹.

Within the FDA CDRH Product Classification database, two primary product codes govern this category:

• Product Code MDA (Elastomer, Silicone, For Scar Management): Applies to standard silicone gel sheets, self-adhesive silicone strips, and topical spreadable silicone fluid gels. Classified as a Class I medical device.
• Product Code PFP (Silicone Hydrogel For Scar Management): Applies to advanced silicone hydrogel formulations and composite scar management gels that incorporate water-binding hydrogel matrices. Classified as a Class I medical device.

A critical milestone in US scar gel regulation occurred on August 9, 2004, when the FDA published a Final Rule in the Federal Register (69 FR 48146) classifying silicone sheeting for scar management into Class I and exempting it from 510(k) premarket notification requirements under section 510(l) of the Federal Food, Drug, and Cosmetic Act, subject to the general limitations of exemptions in 21 CFR 878.9 ².

However, the 510(k) exemption applies strictly to conventional, non-sterile or sterile silicone elastomer sheeting and spreadable gels that act purely through physical mechanism (occlusion and hydration) without active pharmaceutical ingredients, antimicrobial additives, or absorbable components.

A historical audit of the FDA CDRH 510(k) database conducted on August 5, 2026 reveals that FDA has cleared 82 premarket notifications [510(k)s] for silicone scar management devices prior to and alongside the exemption framework (81 under code MDA and 1 under code PFP) ³. Key cleared predicate devices that established the benchmark for clinical safety and equivalence include:

• K002488 — KELO-COTE® Gel (Advanced Bio-Technologies / Alliance Pharma): Self-drying topical silicone gel cleared for the management of old and new hypertrophic and keloid scars resulting from general surgical procedures, trauma, wounds, and burns.
• K932214 — SILON® Silicone Gel Sheeting (Bio Med Sciences, Inc.): Cleared in 1994, establishing early predicate safety for micro-thin silicone elastomer membranes.
• K974354 — MEPIFORM® (Mölnlycke Health Care): Soft silicone dressing with Safetac® technology for scar care.
• K992146 — SCARAID® / Biodermis® (Biodermis): Medical-grade silicone gel sheets for post-surgical scar therapy.
• K024057 — CURAD® Scar Therapy (Beiersdorf, Inc.): Consumer OTC silicone scar pad formulation.
• K131672 — MICROCYN® Scar Management Hydrogel (Oculus Innovative Sciences): Hydrogel-based scar management product registered under code PFP.

For US market entry today, an OTC spreadable silicone scar gel containing 100% medical-grade silicone polymers (e.g., dimethicone, siloxanes) intended for managing closed scars does not require a new 510(k) submission. However, the manufacturer or US importer must comply with FDA Establishment Registration (21 CFR Part 207/807), Device Listing, Quality Management System Regulation (QMSR / 21 CFR Part 820), and maintain an ISO 10993 biocompatibility safety dossier.

How does the EU MDR Class I device vs Cosmetic Regulation boundary work?

In the European Union, the regulatory landscape for silicone scar gels is governed by the Medical Device Regulation (EU 2017/745 - MDR) and the Cosmetic Products Regulation (EC No 1223/2009). Unlike the United States, where 510(k) exemption keeps Class I devices within a streamlined FDA administrative bucket, the EU enforces a sharp 'Borderline' distinction between medical devices and cosmetics ⁵.

According to the European Commission's Manual on Borderline and Classification for Medical Devices under Regulation (EU) 2017/745 (Version 4, September 2023), the classification of a topical gel rests on its primary intended purpose and primary mode of action ⁵:

• MDR Class I Medical Device (Rule 1 / Rule 4): If the product is intended for the prevention, treatment, or management of pathological scar tissue (such as hypertrophic scars, keloids, or contractures resulting from surgery, burns, or trauma) by creating a protective physical barrier that hydrates the stratum corneum and regulates collagenase activity, it is a Class I Medical Device under MDR. The manufacturer must compile an MDR Annex II/III Technical Documentation dossier, execute an EU Declaration of Conformity, appoint an EU Authorised Representative (EC REP), and register the product in EUDAMED.
• Cosmetic Product (Regulation EC 1223/2009): If the product is marketed exclusively for cosmetic or aesthetic improvement of skin surface appearance—such as 'smoothing dry skin', 'improving post-acne skin softness', or 'beautifying skin texture'—without referencing pathological scar repair, medical healing, or keloid prevention, it is governed as a Cosmetic Product. Cosmetic compliance requires a Cosmetic Product Safety Report (CPSR) under Annex I, a designated Responsible Person (RP) in the EU, compliance with Cosmetic GMP (ISO 22716), and notification on the Cosmetic Product Notification Portal (CPNP).

This distinction is further illustrated when comparing scar gels with other topical hygiene and skin products. As detailed in our guide on hypochlorous acid disinfectant classification across the US, EU and China, choosing between medical device, biocidal, or cosmetic regulatory paths requires strict alignment between labeling claims and technical evidence dossiers.

A silicone gel marketed in Europe cannot straddle the fence. Claiming medical scar therapy while attempting to pass through the simpler CPNP cosmetic notification portal is a primary trigger for national competent authority enforcement, product recalls, and sales halts across EU member states.— European Regulatory Compliance Guidance

What are China's NMPA Class II registration rules and intended-use limits?

The regulatory environment in the People's Republic of China, governed by the National Medical Products Administration (NMPA) under State Council Order No. 739, treats silicone scar products with a high level of regulatory oversight. Unlike the US FDA's Class I 510(k)-exempt pathway or the EU's self-declared Class I device pathway, NMPA classifies silicone scar gels and scar dressings as Class II Medical Devices ⁶.

Under the NMPA Medical Device Classification Catalog, scar management products are categorized under Category 14 (Medical Dressings & Protective Materials), sub-category 14-10 (Scar Repair Materials). The typical Chinese registration structure includes:

• Classification: Class II Medical Device (requires formal premarket review and approval by provincial NMPA authorities for domestic products, or national NMPA Beijing for imported products).
• Standard Registration Scope: NMPA medical device registration certificates (e.g., VEMERIX Scar Reduction Gel holding registration certificate Lu Mech Reg. 20212140526) strictly limit the approved intended use to specific, standardized medical terminology.
• Mandatory Approved Intended Use Language: Approved NMPA certificates utilize standard phrases such as: 'For the auxiliary improvement and management of closed hypertrophic scars and keloids caused by surgical procedures, trauma, or burns. Not for use on unhealed or open wounds.'

To obtain an NMPA Class II Medical Device Registration Certificate, the manufacturer or importer must successfully complete:

1. NMPA Type Inspection Testing: Full registered product standard (PTR) testing conducted by an accredited NMPA medical device testing institute in China, verifying viscosity, drying time, heavy metals, pH, sterility/microbial limits, and silicone film thickness.
2. Biocompatibility Evaluation: Full ISO 10993 / GB/T 16886 testing package including cytotoxicity, skin sensitization, and dermal irritation.
3. Clinical Evaluation Report (CER): Comprehensive clinical evaluation demonstrating safety and clinical performance, submitted through either the clinical trial comparison pathway or predicate device comparison pathway under NMPA CER guidelines.
4. Good Manufacturing Practice (GMP) Audit: On-site or documentary NMPA Quality Management System audit verifying compliance with China Medical Device GMP standards.

Distributors importing scar gels into China or OEM buyers sourcing NMPA-registered scar gels from Chinese contract manufacturers must verify that the product's outer box packaging, package insert, and promotional materials match the approved NMPA registration certificate text word-for-word.

What claims are legally permitted, and how do active ingredients change classification?

A primary pitfall for brand owners expanding their aesthetic and dermatological consumable lines is 'claim creep'—adding marketing adjectives or botanical extracts to differentiate their product, without realizing that these additions fundamentally alter the regulatory classification ¹⁵.

Topical silicone scar gels achieve their therapeutic effect through a purely physical mechanism of action: creating a semi-occlusive hydrophobic barrier over the stratum corneum. This barrier reduces trans-epidermal water loss (TEWL), restores epidermal hydration, normalizes keratinocyte signal transduction, and down-regulates excessive fibroblast production of Type I collagen. Because no pharmacological, immunological, or metabolic action is involved, the product remains a medical device.

The boundary between compliant medical device claims, non-compliant drug claims, and cosmetic claims is defined below:

A major risk for OEM brand managers is The Active-Ingredient Trap. Formulators frequently attempt to boost marketing appeal by incorporating active botanical or chemical ingredients into a silicone gel base. The table below outlines how common additives alter regulatory classification across key jurisdictions:

As explored in our analysis of the consumable economics of aesthetic injection and skin-boosting, maintaining strict compliance in consumable formulations protects distributors from sudden regulatory reclassifications and market entry blockages.

What does the clinical evidence (Cochrane vs scar-management guidelines) actually prove?

When building a technical evidence pack for hospital procurement teams or regulatory dossiers, distributors must understand the nuanced landscape of clinical evidence supporting silicone scar management.

On one side of the evidence landscape stand the International Clinical Recommendations on Scar Management (Mustoe et al. 2002; Monstrey et al. 2014; Gold et al. 2014) ⁷. These multi-disciplinary consensus panels unanimously recommend topical silicone gel and silicone gel sheeting as the gold-standard first-line non-invasive therapy for both the prevention and treatment of immature hypertrophic scars and keloids following surgery or trauma.

On the other side stands rigorous evidence-based methodology, represented by the landmark Cochrane Systematic Review (CD013357) titled 'Silicone gel sheeting for treating hypertrophic scars' ⁴. The Cochrane authors conducted a systematic analysis of randomized controlled trials (RCTs), evaluating 13 trials comprising 468 enrolled participants (425 completed).

The key findings and evidence grading from the Cochrane review include:

• Appearance & Texture: Silicone gel sheeting demonstrated a slight benefit in scar thickness and color compared to non-silicone controls, but all included RCTs suffered from high risk of bias, lack of outcome-assessor blinding, and small sample sizes.
• Pain & Pruritus: Silicone gel showed modest reduction in scar pain and itching compared to no treatment, but equivalence to pressure garments and plant extract gels.
• GRADE Certainty Rating: Cochrane rated the overall certainty of evidence across primary outcomes as Low to Very Low due to methodological limitations, imprecise confidence intervals, and publication bias in historical trials ⁴.

This dichotomy between strong clinical guideline consensus and low Cochrane GRADE certainty is not a reason to doubt silicone's utility. Rather, it emphasizes how medical device buyers should position their claims. Clinical guidelines justify recommending silicone scar gel as first-line post-operative care, while Cochrane data warns against making exaggerated claims of guaranteed scar erasure.

What evidence pack and ISO 10993 documents must distributors require from OEM suppliers?

Before signing a distribution agreement or placing a private-label purchase order for silicone scar gel, procurement and regulatory teams should execute a systematic audit of the supplier's technical evidence pack. Extending the methodology outlined in our medical device contract manufacturing buyer evidence checklist, distributors should require the following four-part evidence pack from any prospective scar gel manufacturer:

Part 1: Biocompatibility & Toxicological Safety Pack (ISO 10993)

• ISO 10993-1 Evaluation: Biocompatibility risk assessment for prolonged surface-contact devices touching breached or compromised skin.
• ISO 10993-5 (In Vitro Cytotoxicity): L929 neutral red uptake or MTT assay proving zero cell lysis (Grade 0 or Grade 1 cytotoxicity).
• ISO 10993-10 / 10993-23 (Sensitization & Skin Irritation): Guinea pig maximization test (GPMT) or murine local lymph node assay (LLNA) proving non-sensitizing status, plus primary skin irritation test proving zero erythema and edema.
• Heavy Metals & Volatile Organic Compounds (VOCs): GC-MS residual solvent assay proving complete removal of unreacted siloxane monomers (D4, D5, D6 cyclomethicones) below EU REACH limits.

Part 2: Target Market Labeling & Claim Verification Set

• Primary & Secondary Packaging Art: Outer carton, tube artwork, and Package Insert (IFU) in target market languages.
• Claim Audit Sheet: Verification that all outer box claims match approved product registration scope (e.g., 'closed hypertrophic scars only').
• TEWL & Hydration Performance Study: In vitro or ex vivo water loss barrier data demonstrating occlusion capability.

Part 3: Jurisdictional Registration & Quality System Pack

• ISO 13485:2016 QMS Certificate: Accredited registrar certificate covering design, manufacture, and packaging of topical medical gels.
• US Market Pack: FDA Establishment Registration Number (FEI), Device Listing Number (LBL), and 510(k) exemption rationale document.
• EU Market Pack: EU Declaration of Conformity under MDR 2017/745, MDR Annex II/III Technical Documentation summary, and EC REP agreement.
• China Market Pack: NMPA Class II Medical Device Registration Certificate (e.g., Lu Mech Reg. 20212140526) and approved PTR standard.

Part 4: Sterilization, Stability & Shelf-Life Pack

• Real-Time & Accelerated Stability Data: ISO 11607 and ASTM F1980 accelerated aging test reports supporting stated shelf life (typically 24 to 36 months).
• Preservative Efficacy / Antimicrobial Effectiveness Test: USP <51> or EP 5.1.3 challenge testing proving multidose gel container integrity after repeated opening.
• Package Integrity: Peel strength and burst pressure testing for blister packaging or tube seal integrity.

Where does VEMERIX fit, and how should distributors conduct due diligence?

Within the VEMERIX wound and perioperative care portfolio, the VEMERIX Scar Reduction Gel serves as a dedicated Class II medical device (NMPA Registration Lu Mech Reg. 20212140526) formulated specifically for post-procedure skin recovery, outpatient surgical care, and aesthetic dermatology workflows.

Engineered with high-purity medical-grade silicone polymers, the formulation provides rapid-drying semi-occlusive coverage over closed surgical incisions, circumcision recovery sites, laser vein treatment access points, and traumatic wounds. VEMERIX supports international medical device distributors, hospital procurement groups, and private-label OEM partners by providing:

• Complete Technical & Registration Dossiers: Full ISO 10993 biocompatibility test data, PTR inspection reports, and NMPA Class II registration documents ready for international market entry.
• Flexible OEM & Private-Label Packaging: Custom tube sizing (15 g, 30 g, 50 g), unit-dose packaging, and multi-language carton manufacturing under ISO 13485 quality control.
• Integrated Perioperative Portfolio: Synergistic pairing with VEMERIX wound care consumables, including Hyaluronic Liquid Bandage for superficial abrasions and Medical Cyanoacrylate Adhesive for sutureless skin closure.

However, commercial success begins with rigorous due diligence. We encourage every distributor to independently audit technical dossiers, verify jurisdictional claim boundaries, and request sample evidence packs before commencing commercial rollout.

Frequently Asked Questions

Q1: Is a silicone scar gel a Class I or Class II medical device?
It depends on the regulatory jurisdiction. In the United States, standard topical silicone scar gels are Class I medical devices under 21 CFR 878.4025 (product code MDA). In the European Union, they are Class I medical devices under MDR 2017/745 (Rule 1). In China, NMPA classifies scar repair gels as Class II medical devices under Category 14-10, requiring formal premarket registration approval.

Q2: Can I claim my scar gel 'removes' or 'eliminates' scars?
No. Claims such as 'removes', 'erases', or 'eliminates' scars are legally unsupportable and regulatory non-compliant across the US, EU, and China. Medical device approvals and 510(k) clearances permit only conservative language such as 'manages', 'helps reduce the appearance of', 'flattens and softens', or 'improves discomfort associated with' closed hypertrophic scars and keloids.

Q3: Is a silicone scar gel a cosmetic or a medical device in the EU?
The classification follows the intended purpose claimed by the manufacturer. If the product is marketed for treating, preventing, or managing pathological hypertrophic or keloid scars, it is a Class I Medical Device under MDR (EU 2017/745). If it is marketed solely for non-medical skin surface beautification or softening without mentioning scar tissue management, it falls under Cosmetic Regulation (EC No 1223/2009).

Q4: What ISO 10993 biocompatibility tests does a scar gel need?
Because topical scar gel is a surface device contacting breached or compromised skin over prolonged periods, a complete ISO 10993 safety evaluation is required. Essential tests include ISO 10993-5 (in vitro cytotoxicity), ISO 10993-10 / 10993-23 (skin sensitization and primary skin irritation), and heavy metal / volatile organic compound (VOC) residual monomer analysis.

Q5: Does a silicone scar gel need a 510(k) clearance in the US?
Standard spreadable silicone gels, elastomeric silicone sheets and silicone hydrogel scar gels containing 100% medical-grade silicone polymers for closed scar management are 510(k)-exempt Class I devices under 21 CFR 878.4025 (August 2004 Final Rule) — this exemption covers both product codes MDA and PFP. The exemption is lost only when a product departs from the exempt generic type under § 878.9 — for example by incorporating active drugs or antimicrobial agents, or by claiming a different intended use such as open-wound healing. Those products then require 510(k) clearance or NDA premarket approval.